Turn Therapeutics Inc ARS, filed Oct 19, 2026

Turn Therapeutics Inc. (TTRX)

Turn Therapeutics is developing topical immunomodulator GX-03 for moderate-to-severe eczema and onychomycosis, with an ongoing randomized trial and topline results expected mid-2026. The company also reported 100% recovery of a live VSV vaccine at 14 days ambient storage. AI summary